Evidence map›Paper›PMID 34537829›Full record

ArticleThe international journal of neuropsychopharmacology2022

The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A.

Genís Ona, Frederic Sampedro, Sergio Romero, Marta Valle, Valle Camacho, Carolina Migliorelli, Miguel Ángel Mañanas, Rosa Maria Antonijoan, Montserrat Puntes, Jimena Coimbra and 3 more

Open access · goldAbstract read
In one paragraph

Article in The international journal of neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Triazole 187 is a biased KOR agonist that suppresses itch without sedation and induces anxiolytic-like behaviors in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  2. Kappa opioid receptor control of motivated behavior revisited.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Genís OnaHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Barcelona, Spain.
Frederic SampedroSant Pau Institute of Biomedical Research (IIB-Sant Pau), Barcelona, Spain.
Sergio RomeroDepartment of Automatic Control (ESAII), Biomedical Engineering Research Center (CREB), Universitat Politècnica de Catalunya (UPC), Barcelona, Spain.
Marta ValleDepartament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain.
Valle CamachoNuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Carolina MigliorelliDepartment of Automatic Control (ESAII), Biomedical Engineering Research Center (CREB), Universitat Politècnica de Catalunya (UPC), Barcelona, Spain.
Miguel Ángel MañanasDepartment of Automatic Control (ESAII), Biomedical Engineering Research Center (CREB), Universitat Politècnica de Catalunya (UPC), Barcelona, Spain.
Rosa Maria AntonijoanDepartament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montserrat PuntesCentre d'Investigació de Medicaments, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Barcelona, Spain.
Jimena CoimbraCentre d'Investigació de Medicaments, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Barcelona, Spain.
Maria Rosa BallesterCentre d'Investigació de Medicaments, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Barcelona, Spain.
Maite GarridoCentre d'Investigació de Medicaments, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Barcelona, Spain.
Jordi RibaDepartment of Neuropsychology and Psychopharmacology, Maastricht University, Maastricht,the Netherlands.
Hospital de Sant Pau · ESInstitut d'Investigacions Biomèdiques de Barcelona · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESUniversitat Autònoma de Barcelona · ESMaastricht University · NLUniversitat Politècnica de Catalunya · ESUniversitat Ramon Llull · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe mechanisms through which kappa opioid receptor (KOR) agonists induce psychotomimetic effects are largely unknown, although the modulation of this receptor has attracted attention for its clinical use. In this work, we characterize the neuropharmacological effects of salvinorin-A, a highly selective KOR agonist.

methodsChanges in multimodal electroencephalography, single-photon emission computed tomography, and subjective effects following the acute administration of salvinorin-A are reported. The study included 2 sub-studies that employed a double-blind, crossover, randomized, placebo-controlled design.

resultsThe electroencephalography measures showed a marked increase in delta and gamma waves and a decrease in alpha waves while subjects were under the effect of salvinorin-A. Regarding single-photon emission computed tomography measures, significant decreases in regional cerebral blood flow were detected in multiple regions of the frontal, temporal, parietal, and occipital cortices. Significant regional cerebral blood flow increases were observed in some regions of the medial temporal lobe, including the amygdala, the hippocampal gyrus, and the cerebellum. The pattern of subjective effects induced by salvinorin-A was similar to those observed in relation to other psychotomimetic drugs but with an evidently dissociative nature. No dysphoric effects were reported.

conclusionThe salvinorin-A-mediated KOR agonism induced dramatic psychotomimetic effects along with a generalized decrease in cerebral blood flow and electric activity within the cerebral cortex.

Indexed as

AdolescentAdultChildDiterpenes, ClerodaneDouble-Blind MethodElectroencephalographyFemaleHallucinogensHumansMaleMiddle AgedReceptors, Opioid, kappaYoung AdultDiterpenes, ClerodaneHallucinogensReceptors, Opioid, kappasalvinorin AEEGhallucinogensKappa opioid receptoropioidssalvinorin-ASPECT

Identifiers

PMID34537829
PMCPMC8756086
OpenAlexW3199319624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.